Shopping Cart
Remove All
Your shopping cart is currently empty
Modzatinib
(Synonyms: ITK kinase-IN-1) Copy Product Info
🥰Excellent
Synonyms: ITK kinase-IN-1
Catalog No. T210785 Copy Product Info
Purity: 99.15%
🥰Excellent
Modzatinib (ITKkinase-IN-1) (compound I) is an inhibitor targeting ITK kinase with an IC50 of 8 nM in Jurkat cells, useful for researching inflammatory diseases. Modzatinib (ITKkinase-IN-1) (compound I) inhibits JAK3 in hPBMC cells with an IC50 of 23 nM (based on IL-2/pSTAT5 levels) and shows no inhibitory effect on JAK2. Modzatinib (ITKkinase-IN-1) (compound I) is therefore applied in immunological signaling research to study T-cell receptor–associated kinase pathways, JAK/STAT signaling selectivity, and cytokine response modulation in primary immune cell systems.
Cas No. 2411407-25-3
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $329 | - | In Stock | |
| 5 mg | $787 | - | In Stock | |
| 10 mg | $1,260 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:99.15%
ee:94.72%
Appearance:Solid
Color:White
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Modzatinib (ITKkinase-IN-1) (compound I) is an inhibitor targeting ITK kinase with an IC50 of 8 nM in Jurkat cells, useful for researching inflammatory diseases. Modzatinib (ITKkinase-IN-1) (compound I) inhibits JAK3 in hPBMC cells with an IC50 of 23 nM (based on IL-2/pSTAT5 levels) and shows no inhibitory effect on JAK2. Modzatinib (ITKkinase-IN-1) (compound I) is therefore applied in immunological signaling research to study T-cell receptor–associated kinase pathways, JAK/STAT signaling selectivity, and cytokine response modulation in primary immune cell systems. |
| Targets & IC50 | JAK3:23 nM, ITK:8 nM |
| In vitro | Methods:Whole blood was treated with modzatinib at concentrations of 0.01–1000 ng/mL for 2–18 hours, and its effects on related signaling pathways and gene expression were detected. Results:Modzatinib inhibited aCD3/CD28-induced mRNA expression of IL2 and IFNγ, as well as IL15-mediated activation of pSTAT5 [1]. |
| In vivo | Methods:Rat adjuvant-induced arthritis (AIA) model and mouse T cell transfer colitis model were established. Modzatinib was administered continuously via different routes, and changes in inflammation-related indicators were observed. Results: 1.In rat AIA model, intragastric administration of Modzatinib at 5–15 mg/kg twice daily for 14 consecutive days alleviated ankle swelling in a dose-dependent manner. 2.In mouse T cell transfer colitis model, dietary administration of the compound at 100–300 ppm once daily for 35 consecutive days ameliorated inflammatory lesions in colon and ileum dose-dependently [1]. |
| Synonyms | ITK kinase-IN-1 |
| Molecular Weight | 361.39 |
| Formula | C18H21F2N5O |
| Cas No. | 2411407-25-3 |
| Smiles | N(C1=C2C(=CNC2=NC=N1)[C@@H]3C(F)(F)C3)[C@H]4CN(C(C=C)=O)[C@@H](C)CC4 |
| Storage | Keep away from moisture,Keep away from direct sunlight,Store at low temperature,Store under nitrogen Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: 4.5 mg/mL (12.45 mM), Sonication is recommended. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | |||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: Modzatinib chemical structure | Modzatinib in vivo | Modzatinib in vitro | Modzatinib formula | Modzatinib molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.